Clinical Trials 2018-05-27T07:30:45+00:00

Pennsylvania Retina Specialists physicians have served as principal investigators in many clinical trials at the national level. These trials have investigated new treatments for Age-Related Macular Degeneration (AMD), Diabetic Retinopathy (DR) and many other retinal disorders. The efforts of our physicians and our patients in previous clinical trials have contributed to many of the current treatment regimens used today to treat the retinal disorders.

Active Clinical Trials

  • HAWK EXTENSION— Investigate the safety and efficacy of Brolucizumab/RTH258 vs Eylea for treatment of wet AMD (enrollment currently closed)
  • MAPLE—Evaluate Abicipar for safety and treatment effect in patients with neovascular age-related macular degeneration
  • OPTHEA—Investigate the safety and efficacy of OPT-302 in combination with ranibizumab compared to ranibizumab alone in participants with wet AMD
  • ORACEA— Investigate the efficacy of doxycycline capsules for treatment of dry AMD with geographic atrophy
  • PALADIN—Investigate safety in DME patients treated with ILUVIEN, with primary focus on IOP (enrollment currently closed)
  • PANDA—Evaluate efficacy and safety of Conbercept vs Eylea with wet AMD
  • SEQUOIA—Establish safety and efficacy of Abicipar Pegol compared to Lucentis in patients with wet AMD (enrollment currently closed)
  • TOPAZ—Establish safety and efficacy of triamcinolone acetonide compared to Eylea for patients with retinal vein occlusion

Completed Clinical Trials

  • Lpath NEXUS – Investigate the efficacy of ISONEP as either monotherapy or adjunctive therapy to Lucentis and/or Avastin for treatment of wet AMD.
  • ANCHOR – Investigate the efficacy of Lucentis for treatment of predominantly classic CNV secondary to wet AMD
  • MARINA – Investigate the efficacy of Lucentis for treatment of minimally classic or occult CNV secondary to wet AMD
  • PIER – Investigate the efficacy of different dosing regimens of Lucentis for treatment of CNV secondary to wet AMD
  • SAILOR – Investigate the efficacy of Lucentis for treatment of wet AMD in patients who have had prior treatments
  • HARBOR – Investigate the efficacy of different doses of Lucentis and different regimens for treatment of wet AMD
  • AREDS – Investigate the efficacy of vitamin supplementation (Vitamin A, Vitamin C, Vitamin E and Zinc) on the progression of dry AMD
  • BRAVO – Investigate the efficacy of Lucentis for treatment of CME secondary to branch retinal vein occlusion (BRVO)
  • CRUISE – Investigate the efficacy of Lucentis for treatment of CME secondary to central retinal vein occlusion (CRVO)
  • Thrombogenics – Investigate the efficacy of Microplasmin intravitreal injections for treatment of focal vitreomacular traction
  • HARBOR – Investigate the efficacy of different doses of Lucentis on wet AMD, and different treatment paradigms of Lucentis on wet AMD
  • AREDS-2 – Investigate the efficacy of vitamin supplementation (Lutein, Zeaxanthin, Omega-3) on the progression of dry AMD
  • ForSeeHome Device – Investigate the efficacy of the ForSeeHome Device, an electronic device used at home, in early detection of choroidal neovascularization (CNV) secondary to wet AMD
  • RIDE – Investigate the efficacy of monthly Lucentis injections in the treatment of DME (diabetic macular edema)
  • SHORE – Investigate the efficacy of different dosing regimens of Lucentis injections in the treatment of CME (cystoid macular edema) secondary to RVO (retinal vein occlusions)
  • Alcon RTH258-C001 – Investigate the efficacy and safety of Brolucizumab, an inhibitor to vascular endothelial growth factor (VEGF), in the treatment of wet macular degeneration
  • FOVISTA – Investigate the efficacy of Fovista, an anti-platelet derived growth factor (PDGF) in combination with Avastin or Eylea for treatment of wet macular degeneration.
  • OHR-1601 – Investigate the efficacy of  Squalamine Lactate eye drops in the treatment of wet macular degeneration. 
  • Boulevard—Investigate safety and efficacy of different doses of R06867461 vs Lucentis for DME
  • ONYX—Investigate efficacy, safety, and tolerability of repeated doses of REGN910-3 in patients with wet AMD